Skip to main content
SYRE logo
SYRE
(NASDAQ)
Spyre Therapeutics, Inc.
$47.58-- (--)
Loading... - Market loading

Spyre Therapeutics, Inc. (SYRE) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Spyre Therapeutics, Inc. stock.

Analyst Consensus Rating

Investment consensus from 3 professional research analysts

Consensus Rating

Buy
Based on 3 unique analysts
(6 total ratings in last 90 days)
Low Confidence:1 Buy/Sell

Average Price Target

$70.67
48.53% Upside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest SYRE Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Julian Harrison
BTIG
Strong BuyReiterates
$70.00 $70.00
Alex Thompson
Stifel
Strong BuyMaintains
$70.00 $92.00
Julian Harrison
BTIG
Strong BuyReiterates
$70.00 $70.00
Julian Harrison
BTIG
Strong BuyReiterates
$70.00 $70.00
Yanan Zhu
Wells Fargo
BuyMaintains
$40.00 $50.00
Julian Harrison
BTIG
Strong BuyReiterates
$70.00 $70.00

Frequently Asked Questions

What is the analyst consensus rating for SYRE?

The analyst consensus rating for SYRE is "Buy" based on 3 analyst recommendations.

What is the average price target for SYRE?

The average 12-month price target for SYRE is $70.67, representing an upside of 48.5% from the current price of $47.58.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.